Ernexa Therapeutics Inc. Common Stock (ERNA) — 分析摘要
Ernexa Therapeutics Inc. Common Stock（ERNA）的市值为6.46百万美元，最近一年的营收同比增长了+0.0%。净利润率为-2419.9%。当前市盈率为-0.6倍。
核心要点
- 营收同比变化+0.0%
- 净利润率-2419.9%
- 市盈率-0.6倍
与PHARMACEUTICAL PREPARATIONS板块的其他公司相比，ERNA的营收增长为+0.0%，市盈率为-0.6倍。
Ernexa Therapeutics Inc. Common Stock (ERNA)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
利息保障倍数为 -17.5x — 盈利不足以覆盖利息支出
营收较上一期下降 100.0%。
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
行业
PHARMACEUTICAL PREPARATIONS
员工人数
5
总部
CAMBRIDGE, MA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。